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Abstract
The World Health Organization (WHO) defines Pharmacovigilance as the 
science and activities relating to the detection, assessment, understanding and 
prevention of adverse drug effects. The aim is to promote the safety and effective 
use of medicines through an early detection and evaluation of drug safety risks. The 
pharmacovigilance system is essentially based in spontaneous reports of Adverse 
Drug Reactions (ADR). ADR can be associated with severe outcomes and signifi-
cant mortality, besides, most of them are deemed to be preventable events. Globally, 
antibiotics are among the most widely prescribed medications and their extensive 
use is linked to antibiotic-associated ADR. This chapter aims to summarize available 
epidemiological data concerning antibiotic use related ADR and analyze the reports 
received by the EudraVigilance system regarding the exclusive usage of antibiotics.
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1. Introduction
The history of antibiotics and its use can be dated back to the previous century 
[1]. According to the World Health Organization (WHO), antibiotics are “medi-
cines used to prevent and treat bacterial infections” [2]. These powerful medicines 
are used to destroy specific bacteria, or to prevent their spread, thus not being suit-
able to treat, for instance, viral infections. Over the years, antibiotics have shown 
to effectively treat several previously life-threatening diseases caused by bacteria, 
being the first therapeutic approach in those clinical conditions [3, 4].
The appropriate use of antibiotics is safe, effective and has few adverse effects. 
However, when these medicines are improperly prescribed, bacterial resistance 
may arise. This problem, commonly known as antibiotic resistance (ABR), is one 
of the major public health threats of the 21st century worldwide [4, 5]. Globally, 
the annual predicted number of deaths caused by bacterial agents may increase 
from 700 thousand million deaths to 10 million by 2050, if no action is adopted [5]. 
A study based on data from the European Antimicrobial Resistance Surveillance 
Network (EARS-Net) during 2015 estimated that, annually, around 670 thousand 
infections occur in the European Union (EU) due to antibiotic-resistant bacteria, 
with approximately 33 thousand people dying as a direct outcome of these types 
of infection [6]. The overall crude economic burden of ABR was estimated to be 
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at least 1.5 billion euros a year in the EU, the majority due to hospital costs [7]. 
Consequently, the fight against ABR stands as an extremely important public health 
target that should not be underestimated.
The appropriate use of antibiotics is essential to prevent ABR and reduce the 
risk of adverse reactions. Adverse drug reactions (ADR) are another public health 
problem, namely in terms of mortality, morbidity and healthcare costs, that 
requires maximum attention [8]. An ADR can be defined as “a noxious and unin-
tended response to a medicinal product” [9], and can be caused by any drug class. 
Nevertheless, globally, antibiotics are among the leading drug classes responsible 
for the occurrence of ADR [10, 11].
Pharmacovigilance systems are essential to enhance patients’ care and safety, 
being responsible for the monitoring of pre-market review and post-market surveil-
lance processes. Moreover, they provide reliable and balanced information for an 
effective evaluation of the benefits and risks of available medical drugs [12].
The development of educational interventions to improve the awareness 
of health professionals, and the literacy of the population in general about the 
 dangerous health implications of an inadequate antibiotics use is indispensable.
With this in mind, the aims of this chapter are:
• To review the major antibiotic classes discovered and their mechanisms 
of action;
• To discuss the relevance of an adequate antibiotic use and highlight the main 
barriers associated with the emergence of ABR;
• To describe the importance of establishing good pharmacovigilance practices;
• To summarize available epidemiological data concerning antibiotic use 
related ADR;
• To analyze the reports received by the EudraVigilance system regarding the 
exclusive usage of antibiotics.
2. Antibiotics
The global significance of antibiotics discovery in medical science is unques-
tionable. According to the Centers for Disease Control and Prevention (CDC), 
antibiotics can be described as “medicines that fight infections caused by bacteria 
in humans and animals, by either killing the bacteria or making it difficult for the 
bacteria to grow and multiply” [13]. Antibiotics can be of natural occurring origin 
or chemically synthesized, and have proven to be essential in fighting infectious 
diseases [14]. The discovery and development of these compounds has allowed the 
effective treatment of several bacterial infections, leading to an increased lifespan 
and to an improvement in the quality of life of millions of people [14].
Salvarsan, the first synthetic anti-infective drug reported, was synthesized 
and discovered by Paul Ehrlich, Alfred Bertheim and Sahachiro Hata in 1907. 
This antibiotic had its first clinical application in 1910 in syphilis treatment, and 
was shown to be highly effective and therapeutically safe, regardless of the side 
effects [1, 15, 16]. Afterwards, in 1932, Gerhard Domagk discovered Prontosil, a 
sulfonamide drug, which was further developed and commercially released in 1935 
for public use by the pharmaceutical company Bayer. These were two of the first 
antibiotics of synthetic origin discovered [14–16]. On the other hand, penicillin 
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was the first naturally occurring antibiotic discovered in modern medicine, being 
observed in a petri dish in 1928 by Alexander Fleming. In 1941, Howard Florey, 
Norman Heatly and Ernst Chain pursued Fleming’s studies and penicillin was 
finally produced in sufficient quantities to be used in clinical trials, allowing the 
treatment of uncountable soldiers during World War II. In 1945, the discovery of 
this unprecedent live-saving antibiotic led Fleming, Florey and Chain to won the 
Nobel prize [1, 14–16].
The discovery of these three antibacterial drug agents was remarkable and 
unveiled the future discovery, development and release of several new antibiotic 
classes during the so called “Golden Age” of antibiotics, a period between 1940s and 
middle 1960s [1, 15]. Interestingly, most of the antibiotics discovered during this 
era are still being currently used in the treatment of bacterial infections, once the 
pharmaceutical industry significantly reduced its investments in the production of 
new antibiotics due to the little benefit over existing treatments [3].
Antibiotics are classified in different classes. Some share similar chemical and 
pharmacological features and thus are used in the treatment of similar bacteria 
infections. These classes briefly comprise β-lactams, sulfonamides, aminoglyco-
sides, tetracyclines, chloramphenicol, macrolides, glycopeptides, sulphonamides, 
ansamycins, polymyxins, quinolones, streptogramins, oxazolidinones and lipopep-
tides [16].
According to the Anatomical Therapeutic Chemical (ATC) Index 2020 from the 
WHO Collaborating Centre for Drug Statistics Methodology Norwegian Institute 
of Public Health, antibiotics are categorized as antibacterials for systemic use – J01 
therapeutic subgroup, belong to the anti-infectives for systemic use (J anatomi-
cal group) and consist of the 10 different pharmacological subgroups displayed 
in Table 1 [17]. Additionally, antibiotics can also be categorized as bactericidal or 
bacteriostatic, based on their mechanism of action (Table 1). The general assump-
tion within the society for many years was that bactericidal antibiotics (agents that 
eliminate bacteria by causing cell death) were more powerful and effective than 
bacteriostatic antibiotics (agents that inhibit bacterial growth and reproduction). 
However, it became relevant to assess if this belief was indeed true and verified 
at a clinical level for several bacterial infections [18]. Several studies included in a 
systematic literature review on the topic have shown that for many invasive bacte-
rial infections, such as pneumonia, skin and soft tissue infection, intraabdominal, 
genital and nonendocarditis bloodstream infections, there was no significant 
clinical differences in outcomes nor in mortality. Therefore, one can assume that 
this classification seems to be irrelevant when applied to these types of clinical 
infections [18].
2.1 Main challenges with antibiotic use
The discovery of new antibiotics allowed to save countless lives and revolution-
ize the future of medicine concerning, for instance, transplantation, surgery and 
chemotherapy, by preventing and treating bacterial infections in these patients. 
This has led to a significant decline in mortality and morbidity, and to an extended 
expected lifespan worldwide [19].
After this remarkable era, only a couple of new antibiotic classes were discov-
ered, and the ones that were in clinical use started to become less effective, due to 
the rise of an emerging and global health threat, the ABR [7, 19].
The development of ABR is created by specific modifications in bacteria, namely 
mutations or acquisition of resistant genes by horizontal gene-transfer, allow-
ing them to proliferate and survive in the presence of an antibiotic concentration 
that used to be enough to either prevent the growth or completely eliminate these 
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microorganisms [4]. The ABR phenomenon brought serious health and financial 
consequences to the society, particularly the increased risk in compromising the 
healthcare sector, together with a global economic impact, because the pharma-
ceutical companies no longer perceived both antibiotic discovery and development 
as lucrative investments [19]. Over the past 25 years, several economic, regulatory, 
and scientific barriers arose and led to a significant decline in the production of 
new antibiotics, with only two new classes entering the market and being applied 
into clinical therapy. Instead of generating new drug classes chemically different 
from the existent ones, the pharmaceutical industry chose to modify the already 
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existent antibiotics, particularly the naturally-occurring antibiotics, and to alert for 
its judicious use, aiming to increase their treatment efficiency and combat bacterial 
resistance on the long run [14, 20].
The global prevalence of bacteria resistance to antibiotics has been progressively 
growing. The major facilitating drivers of ABR are the overuse and misuse of these 
drugs, both in human and veterinary medicine and agriculture, as well as the inap-
propriate prescription of antibiotic therapy by health professionals. Additionally, 
ABR can also be triggered by the excessive and unrestricted consumption of 
antibiotics easily available at low price and over the counter for self-medication, in 
countries that lack antibiotic regulations, or by the free online acquisition of these 
medicines in countries where antibiotics are strictly regulated [4, 5, 19].
When an antibiotic successfully reaches its target with a certain required 
concentration, it causes the death or growth inhibition of pathogens. The resistance 
mechanisms frequently used by bacteria can be developed by the modification 
of the antibiotic main target or by the reduction of the antibiotic quantity able to 
reach the target. There are four key molecular mechanisms involved in bacteria 
 resistance [21]:
• Antibiotic modification or destruction – production of specific enzymes able 
to inhibit or destroy the drug through chemical alterations, thus preventing the 
antibiotic to interact with its target;
• Antibiotic uptake decrease and/or antibiotic extruding via efflux pumps – leads 
to a significant reduction in antibiotic’s intracellular concentration, preventing 
it from achieving the target site;
• Target sites modification – either by protecting (antibiotic is unable to achieve 
its binding site) and/or modifying (the affinity between the drug and its target 
is reduced) the target site;
• Bacterial resistance development due to global cell adaptive procedures – 
bacteria are able to survive and protect the disruption of essential cellular 
mechanisms, by developing resistance inside the host environment.
2.2 Epidemiological data
A close link between excessive and inadequate antibiotic consumption and the 
associated ABR spread has been extensively reported in the literature as a public 
health hazard worldwide. Antibiotics overuse and misuse were shown to be two of 
the most critical ABR contributors [5, 19, 20].
The 2019 annual epidemiological report of antimicrobial consumption in the 
EU/European Economic Area (EEA) published by the ECDC disclosed that the 
average total consumption of antibacterials for systemic use (ATC group J01) from 
both primary care and hospital sectors in 2018 was of 19.4 defined daily doses 
(DDD) per 1000 inhabitants per day (ranging from 9.5 in the Netherlands to 34.1 
in Greece). This surveillance report is based on antimicrobial consumption data 
reported by the 28 EU Member States, together with 2 EEA countries (namely, 
Iceland and Norway). Overall, a statistically significant decrease in the trend of 
antibiotics consumption over the 10-year period (2009–2019) was observed in the 
EU/EEA, with statistically significant differences (either a decrease or an increase) 
being noticed for particular countries. Apart from Slovakia, the antibiotic subgroup 
with the highest average consumption in all countries of the EU/EEA was β-lactam 
antibacterials – Penicillins (J01C) [22].
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Approximately two-thirds of the world’s population are living at the Asia Pacific 
region (APAC), one of the largest vulnerable regions to the serious problems posed 
by ABR. Countries belonging to the WHO South-East Asia region were acknowl-
edged to display the greatest risk of ABR development and propagation comparing 
to all WHO regions [23]. The lack of a formal and efficient surveillance system, 
strictly dedicated to detecting and monitor human antibiotic consumption and 
resistance in APAC countries, makes it impossible to determine the overall burden 
and estimates of antibiotic use in this region. Nevertheless, there is a high demand 
for the adoption of successful strategies aiming to decrease the impact of this public 
health threat in Asia, as it is one of the most critical ABR epicenters worldwide [23].
Data on total antibiotic consumption in DDD per 1000 inhabitants per day are 
presented for 2 Asian and 1 African countries of the WHO Eastern Mediterranean 
Region, respectively the Islamic Republic of Iran with 38.8 (wholesalers data), and 
Jordan with 8.9 (import data, with the exception of locally produced medicines that 
would account for a significant fraction of the total antibiotic use), as well as Sudan 
with 35.3 (combined data from import and local manufacturers). The antibiotic 
subgroup most commonly used in Islamic Republic of Iran and Sudan was penicil-
lin, respectively accounting for 33% and 41% of the total consumption, while in 
Jordan more than 50% of the antibiotics consumed were macrolides/lincosamides/
streptogramins (J01F), followed by penicillins and other β-lactam antibacterials 
(J01D) [24].
The same data is also available for 6 countries of the WHO Western Pacific 
Region, including Brunei Darussalam with 5.9 DDD per 1000 inhabitants per day, 
Japan with 14.2, Mongolia with 64.4, New Zealand with 22.7, Philippines with 8.2 
and the Republic of Korea with 27.7. However, Brunei Darussalam and New Zealand 
only provided partial data, either of the public health care or community sectors, 
respectively [24]. Overall, within this region, approximately 33 to 50% of the anti-
biotics used were penicillins. The most commonly consumed antibiotic subgroups 
in Brunei Darussalam, Japan, Mongolia, New Zealand, Philippines and Republic of 
Korea were, respectively, β-lactam antibacterials (70%), macrolides/lincosamides/
streptogramins (32%) and other β-lactam antibacterials (32%), penicillins (33%), 
penicillins (44%), tetracyclines (J01A, 30%) and penicillins (30%) and other 
β-lactam antibacterials (33%) [24].
The WHO African Region only provided total antibiotic consumption data in 
DDD per 1000 inhabitants per day for 4 countries, specifically Burkina Faso with 
13.8, Burundi with 4.4 (data restricted to the public sector), Côte d’Ivoire with 10.7 
and, finally, the United Republic of Tanzania with 27.3 (data reports only from 
2016). The pharmacological subgroup most commonly consumed in all these 4 
countries was penicillin, accounting for about 40% of the total consumption in both 
Burkina Faso and Côte d’Ivoire, 78% in Burundi and 27% in United Republic of 
Tanzania [24].
The ABR threat greatly affects healthcare development, food production, and 
lifespan. To efficiently combat ABR, the 1st step is to prevent bacterial infections, 
the 2nd step is to restrict the resistant bacteria spread by improving an adequate 
antibiotic use and, finally, the 3rd step is to immediately interrupt the spread when 
the development has occurred [25].
According to the CDC’s Antibiotic Resistance Threats in the United States (US) 
Report from 2019, which delivered the most recent national antibiotic resistance-
associated burden estimates, there are still over 2.8 million infections occurring in 
the US per year, yielding more than 350 thousand deaths. Although estimates have 
improved, particularly the death rate which decreased by 18% when compared 
to the same report from 2013, the high number of ABR-associated infections still 
remains an important challenge [25]. Moreover, 2016 CDC estimates revealed that 
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approximately 30% of all antibiotics prescribed in the US, which corresponds to 
about 47 million prescriptions per year, are still being inadequately used to treat 
diseases that do not require antibiotics [26].
Since ABR is a natural and irreversible phenomenon, it is crucial that countries 
around the world start adopting rigorous measures to slow down and inhibit the 
spread of bacterial resistance. In response to the emerging global public health 
threat posed by ABR, a number of national and international actions and initia-
tives have been developed in recent years to address this issue [27]. In 2015, WHO 
adopted a global action plan with several interventions that included strengthening 
health systems and surveillance, reducing the unnecessary use of antibiotics, as 
well as the prevention and control of ABR in humans, animals, agriculture, and 
the environment, highlighting the need for an efficient, indispensable and global 
“OneHealth” approach [27–29]. According to the CDC, the “OneHealth” approach 
is a “collaborative, multisectoral, and transdisciplinary approach—working at the 
local, regional, national, and global levels—with the goal of achieving optimal 
health outcomes recognizing the interconnection between people, animals, plants, 
and their shared environment” [30]. Subsequently, on June 29th, 2017, the European 
Commission adopted a similar integrated action plan, consisting of a series of 
global, rigorous and high priority strategies and measures, designed to restrict the 
development and spread of ABR in humans and animals, based on the “OneHealth” 
perspective [31]. Antibiotic resistance is indeed a One Health challenge, where 
people’s and animal’s health are linked together with the environment, that must be 
rapidly curbed.
The pointless or inadequate antibiotics usage is frequently determined by the 
knowledge, attitudes and beliefs of all the involved stakeholders on this relevant 
topic. In order to fight this threat, a couple of initiatives have been adopted by many 
countries worldwide. These have shown to effectively impact ABR and comprise 
bacterial infection regulatory programs to limit the transmission of resistant 
microorganisms, antibiotic stewardship courses based on the adherence to aware-
ness guidelines and approaches to increase the judicious antibiotic prescription, 
educational interventions among health professionals to improve prudent antibiotic 
prescription and vaccination programs [20, 29, 32–35].
3. Adverse drug reactions associated with antibiotics
Pharmacovigilance is very important for monitoring the safety profile of autho-
rized drugs [12, 36]. The ADR remain a challenge in medicine use and are regarded 
as a critical public health concern due to their potential harmful life-threatening 
effects [37].
According to the European Directive 2010/84/EU, an adverse reaction is defined 
as a “response to a medicinal product which is noxious and unintended”. Moreover, 
these reactions may arise from the use of the medicinal product within or outside 
the terms of the marketing authorization (such as off-label use, overdose, misuse, 
abuse) or from occupational exposure. On the other hand, the definition of an 
adverse effect is given by the EU Directive 2001/20/EC as “any untoward medical 
occurrence in a patient or clinical trial subject administered a medicinal product 
and which does not necessarily have a causal relationship with this treatment”. 
One can then conclude that while an adverse effect is not necessarily triggered by 
the drug, as it is only temporally correlated with the drug use, an ADR is a form of 
adverse effect both temporally and causally associated with the drug [38, 39].
The classical or traditional pharmacological classification of ADR pri-
marily adopted was only differentiating dose-related and non-dose-related 
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reactions, respectively as type A and type B, being solely characterized by 
properties of the drug (its well-known pharmacology and dose dependent 
effects). Subsequently, other 4 types of reactions were further established to 
facilitate the inclusion of adverse reactions that did not belong to type A or 
type B. Therefore, the modern ADR classification currently includes 6 types of 
 reactions [40].
In 2003, to improve the drawbacks and oversimplifications of the traditional 
approach, an alternative and more accurate classification system was proposed by 
Aronson and Ferner, as it had been noticed that some ADR still did not fit well into 
just one of the classes described above. This classification scheme is known as DoTS 
and operates by taking into account 3 major parameters: the Dose responsiveness 
of the drug, the Time course of the reaction and the relevant Susceptibility factors 
of the patient (including genetic, pathological and other biological differences). 
Although this 3-dimensional approach is more precise and comprehensive when 
considering the diagnosis and prevention of ADR, it is also more complex for daily 
use, which prevented its extensive use in the clinic [41].
Globally, ADR have shown to cause significant morbidity and mortality across 
diverse populations, either in hospitalized or ambulatory patients, with a significant 
economic burden to the healthcare system. Adverse reactions affect the quality 
of life of patients, their confidence in the healthcare system and can significantly 
increase hospitalizations and the hospital stay period [42, 43].
Over the years, several studies have reported that on average, ADR are 
responsible for 5–10% of the hospitalizations worldwide, with 80% being 
frequently considered predictable and possibly avoidable reactions (type A). 
Moreover, it has also been shown that approximately one fourth of the ambula-
tory patients in primary care centers can also suffer an ADR reported as serious 
in 13% of the cases [42].
Studies from the US have shown that ADR were observed in over 1.2 million 
hospital stays (about 3.1% of all hospital stays) in 2004. In US hospitals, the inci-
dence of serious and fatal ADR was extremely high, with evaluations of 6.7% and 
0.32% respectively, making ADR between the 4th and 6th leading cause of death. In 
2012, a management consulting firm estimated a profit of USD 115 billion for the 
prevention of 35 million adverse drug events. In United Kingdom, ADR incidence 
among admitted patients was found to be 6.5%, with admissions costing up to £466 
million annually or 0.62% of annual health budget [44]. Within the EU, in 2008 the 
European Commission estimated that around 5% of all hospital admissions were 
triggered by ADR, with 5% of hospitalized patients experiencing an ADR during 
their hospital stay. Additionally, approximately 197 thousand deaths per year took 
place in the EU due to ADR [43].
These findings were undoubtedly one of the starting points for the implementa-
tion of a new EU pharmacovigilance regulatory framework in 2012, to reduce the 
ADR burden [43]. Currently, countless countries around the world already have 
well-established, active and robust national pharmacovigilance systems to safe-
guard patient’s wellbeing.
Some medicines have been especially involved in hospital admissions due to 
ADR, including antibiotics. Inpatients are given at least one antibiotic in about 
50% of the cases, with roughly 20–30% of these being considered unnecessary and 
accounting for 20–50% of drug costs in hospitals [10, 45]. Additionally, a previous 
study has reported that although antibiotics use seems to lead to a small incidence 
of adverse events, its widespread consumption accounts for 23% of all adverse 
events documented [10]. Between 2000 and 2010, developing countries were the 
major contributors to the global rise in antibiotics use and, consequently, in the risk 
of acquiring associated ADR [11].
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There is a lack of studies assessing the incidence of ADR due to antibiotic 
consumption in the hospital sector, during patient’s admission, stay and after 
discharge, as well as its incidence across all antibiotic classes. Nevertheless, the 
available literature has shown the clear contribution of antibiotics to 19% of ADR in 
the emergency department in the US between 2004 and 2006 (with allergic reac-
tions accounting for 79%), 8% linked to hospital admissions in Greece in 2005, 6% 
in Spain between 2001 and 2006, 5% in The Netherlands in 2003, and 11% in India 
between 2002 and 2009, together with 10% of hospital-acquired ADR in the US and 
22% in South Africa [11].
There are several mechanisms explaining different ADR, and the most well-
known include pharmacological causes, idiosyncrasies, hypersensitivity (allergic 
reactions), carcinogenesis and teratogenesis, direct toxicity, chronic exposure, 
drug-disease interaction and drug intolerance [46].
3.1 ADR analysis in Europe: EudraVigilance
EudraVigilance, the official EU pharmacovigilance database managing the col-
lection and analysis of suspected ADR to authorized medical products in the EEA, 
was primarily launched in 2001, with a new format emerging in 2017. This new 
revised and enhanced version aimed to achieve an improved effective monitoring of 
the medicine safety, contributing to public health protection, and the communica-
tion of validated signals to the European Medicines Agency (EMA) and the national 
medicines regulatory authorities, in line with the legislative framework. By the end 
of 2017, submissions to EudraVigilance overcome the 12 million individual case 
safety reports (ICSR), referring to around 8 million individual cases, and making it 
one of the largest spontaneous reporting systems worldwide [47].
As previously mentioned, one of the drug classes most commonly prescribed 
and responsible for ADR, both in primary care and hospital sectors, are antibiot-
ics. For Portugal, according to the data provided by the System of Information and 
Monitoring of the Portuguese National Health System (SIM@SNS) platform [48], 
developed by the shared services of the Health Ministry, the four antibacterials for 
systemic use mostly prescribed during the last couple of years (2018–2020) were: a 
combination of Amoxicillin and Clavulanic acid (I), Azithromycin (II), Amoxicillin 
(III) and Fosfomycin (IV) [49]. In particular, during the year of 2019, the total 
number of antibiotic packages prescribed within the public sector accounted for 
around 4.5 million, from which 1.27, 0.63, 0.52, and 0.35 million, respectively cor-
responded to I, II, III and IV. Data from 2018 revealed the same trend as 2019. Until 
August 2020, the only alteration observed was the increase in fosfomycin prescrip-
tions over amoxicillin [49].
The individual safety reports stored at the VigiBase (for I) [50] and 
EudraVigilance (for II, III and IV) [51] databases at 14th November 2020 revealed 
that among all ADR reported, the most affected System Organ Classes (SOC) for 
each antibiotic were1:
I. Combination of Amoxicillin and Clavulanic Acid (ICSR total = 140942): 
Skin and subcutaneous tissue disorders – 50.5%, Gastrointestinal disorders 
– 24.9%, and General disorders and administration site conditions – 11.9%. 
Within all ADR reported for this combination, 24.6% were considered 
serious ADR;
1 The antibiotic-associated ADR reported data are displayed in different ways, as they were retrieved 
from two different databases, VigiBase (for I) and EudraVigilance (for II, III and IV).
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II. Azithromycin (ICSR total = 13404): Gastrointestinal disorders – 26.2% (of 
which 15.6% were serious), Skin and subcutaneous tissue disorders – 24.7% 
(of which 17% were serious) and General disorders and administration site 
conditions – 24.5% (of which 20.2% were serious);
III. Amoxicillin (ICSR total = 34427): Skin and subcutaneous tissue disorders – 
56.2% (of which 36% were serious), Gastrointestinal disorders – 18.4% (of 
which 10.9% were serious) and General disorders and administration site 
conditions – 16.1% (of which 11.8% were serious);
IV. Fosfomycin (ICSR total = 2483): Gastrointestinal disorders – 38.6% (of 
which 10.1% were serious), Skin and subcutaneous tissue disorders – 24.8% 
(of which 12.6% were serious) and General disorders and administration 
site conditions – 21.3% (of which 11.2% were serious).
The most common ADR reported within each SOC caused by the consumption 
of these antibiotics include rash, urticaria and pruritus for skin and subcutaneous 
tissue disorders, diarrhea, nausea, vomiting and abdominal pain for gastrointes-
tinal disorder and pyrexia, malaise, fatigue and asthenia for general disorders and 
administration condition sites.
The use of antibiotics can result in ADR, among which hypersensitivity reac-
tions. One of the safest and more effective antibiotic subgroups is the β-lactam 
antibacterials. Within this subgroup, penicillin is one of the most prescribed 
antibiotics worldwide and is frequently associated with reported allergic reactions. 
Around 10% of the global population report an allergy to β-lactams, leading to an 
increased use of broad-spectrum antibiotics, promoting the risk for the develop-
ment of resistant bacteria and adverse effects, together with an increased cost. Most 
reports of penicillin allergy describe an unknown or a mild cutaneous reaction. 
The estimated frequency of the more serious anaphylactic reactions to penicillin is 
roughly 0.02% to 0.04%, being rarer after oral or cutaneous exposure [52].
3.2 Special populations: children, pregnant women and older adults
ADR reporting system databases are of great utility in the early detection of 
medicine safety issues [8]. Most of the available data regarding ADR prevalence 
refer to adult populations within a hospital context [53]. Thereby, it is extremely 
important to increase our knowledge and perception on ADR incidence in special 
populations, such as the pediatric (0–18 years old), pregnant women and older 
adults (≥ 65 years old), as they may differ regarding the most frequently involved 
drugs and ADR manifestations, and may be at an increased risk due to their general 
exclusion from pre-marketing clinical assays.
3.2.1 Children
Antibiotics are among the most commonly prescribed drugs in children. Reports 
from a study conducted in the US during 2016 revealed that 47.4% of infants 
between 0 and 4 years old received at least one antibiotic prescription, when com-
pared to 39.8% of the adult population. Although these drugs are very valuable for 
the treatment of severe infection diseases, its high and inadequate consumption can 
frequently lead to an increased bacterial resistance, as well as to the occurrence of 
adverse effects even if mild and spontaneously resolving [54]. Antibiotics have been 
repeatedly reported as the leading contributors to ADR in children. Children can be 
at an increased risk due to their anatomical and physiological characteristics, such 
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as their immature immune systems, especially in the first years of life. Moreover, 
there is a frequent abuse and misuse of these drugs in pediatric clinical practice due 
to lack of pharmacokinetics data or dose-finding studies, and many antibiotics are 
prescribed on an unlicensed or “off-label” basis as they were only tested and autho-
rized for adults. Although many adverse events are equal in children and adults, 
with age not contributing to the frequency and severity of the ADR, there are a few 
number of antibiotic-associated ADR depending on the unique pharmacokinetic 
and pharmacodynamic features of the antibiotic that can differ significantly with 
age, particularly when administered to newborns and infants [54].
A systematic review [55] of ADR in pediatric patients reported that the overall rates 
of hospital admissions caused by ADR ranged from 0.4% to 10.3% of all children, while 
the ADR incidence rate varied between 0.6% and 16.8% among children exposed to a 
drug during hospital stay [8, 53]. Furthermore, a study performed between 2011 and 
2015 in the US, based on 6542 surveillance cases, estimated that approximately 70 thou-
sand annual emergency department visits were made for antibiotic-associated ADR 
among children. This review also showed that the antibiotic most commonly associated 
with ADR was, by far, the oral penicillin (55.7%), and the most typical clinical manifes-
tations attributed to antibiotics were allergic reactions. Within the pediatric population, 
amoxicillin was found to be the antibiotic most frequently implicated among children 
under 10 years old [56]. The findings obtained from ADR reports of two studies con-
ducted within the Portuguese pediatric population between 2003 and 2012 (age range 
0–17 years old) and 2006 and 2016 (age range 10–18 years old) demonstrated that 
the most representative ADR identified involved the subsequent top 4 SOC: general 
disorders and administration site conditions, followed by skin and subcutaneous tissue 
reactions, nervous system disorders and gastrointestinal disorders. Antibacterials for 
systemic use were the second most represented group after vaccines [8, 53].
The individual safety reports stored at the VigiBase (for I) [50] and 
EudraVigilance (for II, III and IV) [51] databases revealed that, among all ADR 
reported specifically for children, the percentage of antibiotic-associated ADR for 
the antibiotics mostly prescribed in Portugal between 2018 and 2020 was of 16.6% 
for I (combination of amoxicillin and clavulanic acid), 17.1% for II (azithromycin), 
17.7% for III (amoxicillin) and 4.2% for IV (fosfomycin). Moreover, the most 
affected SOC were2:
II. ICSR total = 2297: Skin and subcutaneous tissue disorders – 35%, 
Gastrointestinal disorders – 25% and General disorders and administration 
site conditions – 19.5%;
III. ICSR total = 6105: Skin and subcutaneous tissue disorders – 69.3%, 
Gastrointestinal disorders – 16.9% and General disorders and administra-
tion site conditions – 14.1%;
IV. ICSR total = 107: Gastrointestinal disorders – 27.1%, Skin and subcutane-
ous tissue disorders – 25.2% and General disorders and administration site 
conditions – 22.4%.
3.2.2 Pregnant women
People are aware about the existent lack of information concerning drug safety 
during pregnancy, mainly because pregnant women are often excluded from trials 
2 SOC data for the combination of amoxicillin and clavulanic acid (I) were not available at VigiBase.
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throughout the clinical development of the drug. Since 1980, estimates indicate that 
only 10% of the authorized drugs have enough data involving child risk in preg-
nancy. Thus, there is a high need for epidemiological studies in pregnant women 
aiming to evaluate the incidence of ADR [57].
Since there are no reports of totally innocuous drugs commercially available, 
pregnant women must be cautious and try to avoid, as much as possible, the con-
sumption of medicines, particularly during the first trimester, and only use them 
when the benefits to the mother outweigh the fetus risk [58]. Over the last years, it 
has been observed a rise in the number of women consuming drugs during preg-
nancy. Antibiotics are among one of the classes most commonly prescribed to treat 
infections in pregnant women, constituting nearly 80% of all drugs prescription, of 
which roughly 1 in every 4 women consume at least one antibiotic throughout their 
pregnancy course. However, its use must be prudent as the first concern is to protect 
the fetus from potential ADR resulting from antibiotic use [57, 58]. Urinary tract 
infections, sexually transmitted infections and upper respiratory tract infections 
represent 3 of the most typical infectious diseases found during pregnancy. When 
not treated, urinary tract and sexually transmitted infections represent an impor-
tant risk to the fetus with consequences such as, as low birth weight, prematurity 
and spontaneous abortion. Moreover, the risk for short-term (congenital abnor-
malities) and long-term (changes in the gut microbiome, asthma, atopic disease) 
effects in the newborn, and physiological changes that usually take place during 
pregnancy, have also been related to antibiotic therapy [57].
Overall, there are several antibiotics that can be generally used during preg-
nancy without compromising safety, such as β-lactams (with penicillin and 
derivatives being the most prescribed drugs to pregnant women), vancomycin, 
macrolides, clindamycin, and fosfomycin, and others that must be mostly avoided, 
such as fluoroquinolones and tetracyclines [57]. In fact, penicillins have a long 
safety track record during pregnancy, but are usually substituted by macrolides as 
alternative for patients with penicillin allergies. Very recently, a cohort population-
based study from UK has shown that the prescription of macrolides instead of 
penicillin antibiotics led to an enhanced risk of major malformation, primarily 
those derived from the cardiovascular system, but only over the first pregnancy tri-
mester. This study also reported an enhanced risk of genital malformations linked 
to macrolides prescription in any trimester, advertising for the careful use of this 
antibiotic subgroup in pregnant women [59]. Some studies have also indicated an 
increased asthma risk in early childhood, as well as an increased risk of childhood 
epilepsy and obesity linked to antibiotic use during pregnancy [58].
The use of 3 of the most prescribed antibiotics in Portugal over the last years, 
namely amoxicillin clavulanate, amoxicillin and fosfomycin, has been considered 
safe and well-tolerated during pregnancy, with no adverse effects being shown in 
the fetus or infant [57].
3.2.3 Older adults
Infectious diseases in the elderly population remains a public health concern 
because of the high mortality and morbidity outcomes. The geriatric population, 
regarded as a special population by the International Council for Harmonization 
(ICH), is more prone to develop ADR because they usually exhibit a combination 
of increased critical risk factors that can promote these reactions. These risk factors 
comprise multimorbidity, polypharmacy, changes in medication adherence, phar-
macokinetics, greater vulnerability, aging-related physiological changes (changes 
in the body mass distribution, renal function, metabolic capacity and alteration 
in blood protein levels), deficit in the immune system, weakening cognition, in 
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addition to a clear lack on drug use information in the older people [60]. Research 
studies have estimated an ADR risk in older adults of four times higher than the 
rest of the population. Old age is also a critical factor for extended hospital stays, 
enhanced prevalence of complication and falls. The large majority of reported 
ADR in the older adults belong to type A, possibly avoidable and linked to com-
monly prescribed drugs. Common geriatric syndromes from older adults include 
delirium, falls, dizziness, urinary incontinence, which can sometimes be mistaken 
with typical manifestations from older people. Therefore, given their heterogeneity, 
to efficiently prevent the high ADR incidence in the older people, it is essential to 
focus on person-centered care intervention allied to good clinical practice [60].
Between 2007 and 2009, data from an US report on hospitalizations after emer-
gency department visits for adverse events revealed that 3.8% of the total hospital-
izations were due to the use of antimicrobial agents. In fact, these agents were the 
5th most common treatment class involved in hospitalizations. Data showed that the 
most frequent clinical adverse event manifestations arisen from antimicrobials use 
leading to hospitalizations were allergic reactions (36.2%), dyspnea and weakness 
(22.5%), gastrointestinal effects (20.5%), and neurologic effects (18.3%). Some of 
these adverse events, such as dyspnea, weakness, neurological adverse events, and 
effects on blood pressure may potentially promote significant negative implications 
in older patients, leading to altered mental status, falls, and hypotension [61].
The individual safety reports stored at the VigiBase (for I) [50] and 
EudraVigilance (for II, III and IV) [51] databases revealed that, among all ADR 
reported specifically for older adults (≥ 65 years old), the percentage of antibiotic-
associated ADR for the antibiotics mostly prescribed in Portugal between 2018 and 
2020 was of 22.7% for I (combination of amoxicillin and clavulanic acid), 20.7% 
for II (azithromycin), 22.7% for III (amoxicillin) and 31.5% for IV (fosfomycin). 
Moreover, the most affected SOC were3:
II. ICSR total = 2767: General disorders and administration site conditions 
– 26.5%, Gastrointestinal disorders – 21.5% and Skin and subcutaneous 
tissue disorders – 21%;
III. ICSR total = 7813: Skin and subcutaneous tissue disorders – 47.8%, 
Gastrointestinal disorders – 18% and General disorders and administration 
site conditions – 16.5%;
IV. ICSR total = 780: Gastrointestinal disorders – 33.2%, Skin and subcutane-
ous tissue disorders – 27.1% and General disorders and administration site 
conditions – 21.8%.
4. Conclusions
Overall, antibiotics are undoubtedly among the most successful drug agents in 
the world. They are attributed to having improved patient care and revolutionized 
modern medicine. However, the inappropariate prescribing of these agents has 
led to the development of one of the biggest public health concern: antimicrobial 
resistances [4, 5]. Therefore, it is vital to understand and overcome the main bar-
riers and challenges resulting from antibiotics usage, aiming to design and develop 
educational interventions for increase awareness and knowledge within the society, 
and hopefully be able to change people’s and prescribing physician’s behavior.
3 SOC data for the combination of amoxicillin and clavulanic acid (I) were not available at VigiBase.
15
Prevalence and Significance of Antibiotic-Associated Adverse Reactions
DOI: http://dx.doi.org/10.5772/intechopen.98673
Pharmacovigilance is a global top priority in healthcare systems. It provides 
instruments for monitoring the safety of medicines on the market through 
prevention, detection and assessment of adverse reactions, as well as invaluable 
information on the benefit/risk ratio of a health product throughout its life cycle 
[12, 36].
Currently, ADR are still ranked among the leading mortality causes in many 
countries and are recognize as hazards of drug therapy [42, 43]. Although ADR are 
prevalent in all ages, it is more difficult to predict the effect of the drugs among the 
special populations that do not take part in clinical trials. Post-marketing surveil-
lance through pharmacovigilance centers is extremely important and the most 
efficient way to monitor ADR, especially for those groups [12, 42].
Although antibiotics are considered safe when rationally used for treatment and 
prophylaxis of several infectious diseases, with its prescription being generally high 
among all ages, these drugs can also substantially contribute to reported ADR, espe-
cially β-lactam antibacterials, and macrolides [10, 11, 45]. The most affected organ 
systems involved are the gastrointestinal system and the skin.
In sum, a visible reduction in global human mortality and morbidity, as well as 
in health costs, would certainly be noticed with the implementation of international 
and national campaigns alerting to both the rational use of antibiotics and the 
importance of reporting ADR, aiming to minimize patient’s harm and significantly 
improve public health.
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Appendices and nomenclature
ABR Antibiotic Resistance
ADR Adverse Drug Reactions
APAC Asia Pacific region
ATC Anatomical Therapeutic Chemical
CDC Centers for Disease Control and Prevention
DDD Defined Daily Doses
EARS-Net European Antimicrobial Resistance Surveillance Network
EEA European Economic Area
EMA European Medicines Agency
EU European Union
ICH International Council for Harmonization
ICSR Individual Case Safety Report
SOC System Organ Classes
US United States
WHO World Health Organization
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